company background image
ADO

AnteoTechASX:ADO Stock Report

Market Cap

AU$492.6m

7D

8.7%

1Y

127.3%

Updated

22 Oct, 2021

Data

Company Financials +
ADO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ADO Overview

AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for AnteoTech
Historical stock prices
Current Share PriceAU$0.25
52 Week HighAU$0.077
52 Week LowAU$0.49
Beta0.94
1 Month Change-7.41%
3 Month Change11.11%
1 Year Change127.27%
3 Year Change1,462.70%
5 Year Change354.55%
Change since IPO-10.71%

Recent News & Updates

Oct 09
We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, AnteoTech ( ASX:ADO...

Shareholder Returns

ADOAU Life SciencesAU Market
7D8.7%7.3%0.7%
1Y127.3%5.8%21.4%

Return vs Industry: ADO exceeded the Australian Life Sciences industry which returned 5.8% over the past year.

Return vs Market: ADO exceeded the Australian Market which returned 21.4% over the past year.

Price Volatility

Is ADO's price volatile compared to industry and market?
ADO volatility
ADO Beta0.94
Industry Beta0.95
Market Beta1

Stable Share Price: ADO is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ADO's weekly volatility has decreased from 20% to 15% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
1995n/aDerek Thomsonhttps://www.anteotech.com

AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. The company’s products include AnteoCoat, which comprise a suite of compounds that enable the control of material interactions and properties in the energy storage applications; AnteoBind ready-to-use kits to streamline and improve the conjugation process; and EuGeni, a COVID-19 antigen rapid test. It has collaboration agreements with Axxin for COVID-19 anigen test.

AnteoTech Fundamentals Summary

How do AnteoTech's earnings and revenue compare to its market cap?
ADO fundamental statistics
Market CapAU$492.60m
Earnings (TTM)-AU$6.22m
Revenue (TTM)AU$2.30m

215.5x

P/S Ratio

-79.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADO income statement (TTM)
RevenueAU$2.30m
Cost of RevenueAU$0
Gross ProfitAU$2.30m
ExpensesAU$8.51m
Earnings-AU$6.22m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0032
Gross Margin100.00%
Net Profit Margin-270.33%
Debt/Equity Ratio0%

How did ADO perform over the long term?

See historical performance and comparison

Valuation

Is AnteoTech undervalued compared to its fair value and its price relative to the market?

23.34x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ADO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADO is unprofitable, so we can't compare its PE Ratio to the Global Life Sciences industry average.

PE vs Market: ADO is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADO is overvalued based on its PB Ratio (23.3x) compared to the AU Life Sciences industry average (5.2x).


Future Growth

How is AnteoTech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

66.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: ADO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ADO's is expected to become profitable in the next 3 years.

Revenue vs Market: ADO's revenue (49.6% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: ADO's revenue (49.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ADO's Return on Equity is forecast to be very high in 3 years time (69%).


Past Performance

How has AnteoTech performed over the past 5 years?

17.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADO is currently unprofitable.

Growing Profit Margin: ADO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADO is unprofitable, but has reduced losses over the past 5 years at a rate of 17.2% per year.

Accelerating Growth: Unable to compare ADO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (59.8%).


Return on Equity

High ROE: ADO has a negative Return on Equity (-29.44%), as it is currently unprofitable.


Financial Health

How is AnteoTech's financial position?


Financial Position Analysis

Short Term Liabilities: ADO's short term assets (A$21.8M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: ADO's short term assets (A$21.8M) exceed its long term liabilities (A$1.5M).


Debt to Equity History and Analysis

Debt Level: ADO is debt free.

Reducing Debt: ADO has no debt compared to 5 years ago when its debt to equity ratio was 20.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADO has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ADO has sufficient cash runway for 3 years if free cash flow continues to grow at historical rates of 15.6% each year.


Dividend

What is AnteoTech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADO's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Derek Thomson

2.17yrs

Tenure

AU$437,917

Compensation

Mr. Derek Thomson serves as Chief Executive Officer at AnteoTech Limited (formerly known as Anteo Diagnostics Limited) since August 8, 2019. He is an accomplished executive and has held senior roles with p...


CEO Compensation Analysis

Compensation vs Market: Derek's total compensation ($USD327.95K) is below average for companies of similar size in the Australian market ($USD716.52K).

Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ADO's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: ADO's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ADO insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.7%.


Top Shareholders

Company Information

AnteoTech Limited's employee growth, exchange listings and data sources


Key Information

  • Name: AnteoTech Limited
  • Ticker: ADO
  • Exchange: ASX
  • Founded: 1995
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$492.598m
  • Shares outstanding: 1.97b
  • Website: https://www.anteotech.com

Number of Employees


Location

  • AnteoTech Limited
  • Brisbane Technology Park
  • Unit 4
  • Eight Mile Plains
  • Queensland
  • 4113
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/22 15:37
End of Day Share Price2021/10/22 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.